PBAC's latest decision on Direct-acting antiviral (daa) regimens: Noted (2019). Considered for Treatment of chronic hepatitis C virus (HCV) infection. The submission addresses changes to PBS listings and conditions for DAA regimens following a clinical stakeholder meeting.
PBAC outcome
Noted
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Patients with chronic hepatitis C virus infection eligible for treatment with direct-acting antiviral regimens, including those in corrective services and hospital settings.
Therapy area
Hepatology
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
Eligible patients/year
19,000
ICER note
This is a stakeholder advice item regarding listing conditions and administrative changes; no economic evaluation or ICER is presented.
Risk sharing
Risk-sharing arrangement in place — Risk share arrangements are mentioned as existing arrangements that would need to be considered in any changes to streamlined authority listings for DAA regimens.